Etira Doses First Patient in Clinical Trial
Etira has announced that their first patient in our ERX-315-101 Phase 1 trial has received their initial doses of ERX-315 at The Kinghorn Cancer Centre in Sydney, Australia. ERX-315, Etira’s first-in-class small molecule drug, is designed to selectively induce catastrophic stress in cancer cells. This first-in-human trial evaluates its safety and tolerability in patients with advanced solid tumors unresponsive to approved therapies.
Etira Doses First Patient in Clinical Trial